AMNEAL PHARMACEUTICALS, INC. Depreciation
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Depreciation of $57.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-27
- AMNEAL PHARMACEUTICALS, INC. depreciation for the quarter ending 2018-12-31 was $18.62M, a 56.19% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. depreciation for the quarter ending 2018-09-30 was $17.36M, a 62.53% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. depreciation for the quarter ending 2018-06-30 was $15.45M, a 60.13% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. depreciation for the quarter ending 2017-12-31 was $11.92M.
- AMNEAL PHARMACEUTICALS, INC. depreciation for fiscal 2025 was $57.30M, a 8.47% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. depreciation for fiscal 2024 was $62.60M, a 5.44% decline from fiscal 2023.
- AMNEAL PHARMACEUTICALS, INC. depreciation for fiscal 2023 was $66.20M, a 2.79% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. depreciation for fiscal 2022 was $68.10M, a 12.19% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $57.30M 10-K · filed 2026-02-27 | ||||
| 2024-12-31 | $62.60M 10-K · filed 2026-02-27 | ||||
| 2023-12-31 | $66.20M 10-K · filed 2026-02-27 | ||||
| 2022-12-31 | $68.10M 10-K · filed 2025-02-28 | $68.11M 10-K · filed 2023-03-03 | |||
| 2021-12-31 | $60.70M 10-K · filed 2024-03-14 | $60.70M 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $60.42M 10-K · filed 2023-03-03 | ||||
| 2019-12-31 | $63.28M 10-K · filed 2022-03-01 | ||||
| 2018-12-31 | $18.62M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $35.97M derived: sum of 2 quarters · filed 2021-03-01 | $51.43M derived: sum of 3 quarters · filed 2021-03-01 | $64.42M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $17.36M 10-Q · filed 2018-11-07 | $32.81M derived: sum of 2 quarters · filed 2018-11-07 | $45.80M 10-Q · filed 2018-11-07 | ||
| 2018-06-30 | $15.45M 10-Q · filed 2018-08-09 | $28.44M 10-Q · filed 2018-08-09 | |||
| 2017-12-31 | $11.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $22.60M derived: sum of 2 quarters · filed 2020-03-02 | $32.25M derived: sum of 3 quarters · filed 2020-03-02 | $41.96M 10-K · filed 2020-03-02 | |
| 2017-09-30 | $10.68M 10-Q · filed 2018-11-07 | $20.33M derived: sum of 2 quarters · filed 2018-11-07 | $30.04M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | $9.65M 10-Q · filed 2018-08-09 | $19.36M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $29.31M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |